Delonix is a leading biotech company dedicated to developing next-generation genetically engineered bacterial vaccines. Founded by experts in synthetic biology and vaccinology, Delonix has developed complete toolkits for engineering 16+ pathogens, many of which are in WHO Bacterial Priority Pathogens List, 2024. Leveraging our advanced pathogen-editing capabilities, we have established several vaccine platforms, including OMV Plus (engineered OMV vaccine platform), BioDVax (Biodesigned bacterial factory for subunit vaccine), and ProBVax (Programming bacterial cells for whole cell vaccine). Through these proprietary platforms, we have developed a range of innovative bacterial vaccine pipelines and established vaccine development and licensing agreement with industry partners.